Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 6.1% in the afternoon session after the company announced it delivered the first mRNA vaccines fully manufactured in Canada to the nation's provinces and territories.
Wall Street is on track for its third straight day of gains, with major large-cap indices extending records as investors remain optimistic about corporate earnings and upcoming rate cuts.
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Moderna shares are trading marginally lower Wednesday morning. Tuesday's rally was driven by the release of positive preliminary data for its updated 2025-2026 Spikevax formula.
On Tuesday, U.S. markets slipped, with the Dow Jones Industrial Average falling about 0.3% to 45,757.90, the S&P 500 retreating 0.1% to 6,606.76, and the Nasdaq edging down 0.07% to 22,333.96.These are the top stocks that gained the attention of retail traders and investors throughout the day.
Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 variant of COVID-19.
